Oregon donors help OHSU expand access to eye exams, treatment and education statewide
Asian Health & Service Center vaccinations
Jenny Zhu, student in the OSU/OHSU College of Pharmacy, vaccinates a patient at the Asian Health & Service Center clinic March 27, 2021 in southeast Portland. (OHSU/Erin Hoover Barnett)
Asian Health & Service Center vaccinations
Retired OHSU faculty member Mark Bajorek, M.D., left, volunteered through Multnomah County to support OHSU learners like An Ruan, a second-year Physician Assistant student, who administered vaccines at the Asian Health & Service Center March 27, 2021. (OHSU/Erin Hoover Barnett)
Asian Health & Service Center vaccinations
The student-run Bridges Collaborative Care Clinic has forged community partnerships to expand the clinics impact, including, from left, Holden Leung, CEO of Asian Health & Service Center, which hosted the clinics for seniors; Multnomah County Commissioner Sharon Meieran, who visited the clinic March 27; Erik Szeto, D.O., founder and chairman of AHSC, and Anita Chan, M.D., Providence Health & Services physician and Szetos wife. (OHSU/Erin Hoover Barnett)
OHSU students help vaccinate Asian American seniors
OHSU retains former U.S. Attorney General Eric Holder of Covington & Burling to lead comprehensive, independent investigation of institutional harassment, discrimination, retaliation and racism
Lina Reiss
How to prepare for a healthy transition to in-person learning
Klaus Frueh and Scott Hansen
Klaus Frueh, Ph.D.(left), Scott Hansen, Ph.D., and colleagues at the OHSU Vaccine and Gene Therapy Institute lead the development of a cytomegalovirus-based vaccine platform that is now being tested to stop HIV in people. After 20 years of development, the experimental vaccine’s OHSU development team have published research that explains the unique biological mechanisms that make the technology work. (OHSU/Kristyna Wentz-Graff)
Louis Picker
Louis Picker, M.D., (right) and colleagues at the OHSU Vaccine and Gene Therapy Institute lead the development of a cytomegalovirus-based vaccine platform that is now being tested to stop HIV in people. After 20 years of development, the experimental vaccine’s OHSU development team have published research that explains the unique biological mechanisms that make the technology work. (OHSU/Boone Speed Photography)